Is It Normal on a GLP-1? Eight Common Questions, Answered From the Labels

The fastest way to answer any is-it-normal question about a GLP-1 medication is to look at the adverse-reaction table in the drug's own prescribing information, because that table is a count of what people in the pivotal trials actually reported compared with people on placebo. For Wegovy (semaglutide, Novo Nordisk), the June 2026 FDA label pools three 68-week placebo-controlled trials in 2,116 adults with obesity or overweight. Its Table 3 lists nausea in 44% of people on the once-weekly injection versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, constipation in 24% versus 11%, abdominal pain in 20% versus 10%, headache in 14% versus 10%, fatigue in 11% versus 5%, dyspepsia in 9% versus 3%, dizziness in 8% versus 4%, abdominal distension and eructation each in 7% (versus 5% and under 1%), flatulence in 6% versus 4%, gastroesophageal reflux disease in 5% versus 3%, and hair loss in 3% versus 1%.

For Zepbound (tirzepatide, Eli Lilly), the August 2026 label pools two 72-week trials in 2,519 adults. Its Table 1 gives a range across the three maintenance doses: nausea 25% to 29% versus 8% on placebo, diarrhea 19% to 23% versus 8%, constipation 11% to 17% versus 5%, vomiting 8% to 13% versus 2%, fatigue 5% to 7% versus 3%, eructation 4% to 5% versus 1%, hair loss 4% to 5% versus 1%, and dizziness 4% to 5% versus 2%. Mounjaro, the same tirzepatide molecule approved for type 2 diabetes, reports in its August 2026 label a shorter table in a diabetes population: nausea 12% to 18% versus 4%, decreased appetite 5% to 11% versus 1%, and constipation 6% to 7% versus 1%.

Two cautions that the labels themselves print. First, these are trial populations on a fixed escalation schedule with a reduced-calorie diet, and the labels state that rates observed in one drug's trials cannot be directly compared with another's. Second, being on the list means the symptom was common enough to count, not that it is harmless in every form: the same documents carry warnings for pancreatitis, gallbladder disease, dehydration leading to kidney injury and hypoglycemia. The sections below take the eight questions people actually type and place each one on the right side of that line. For the full tables and the warnings in one place, our overview of GLP-1 side effects is the reference page.

Yes, this is normal in the specific sense that the manufacturers expected it and wrote it down. The Wegovy label, describing gastrointestinal adverse reactions in adults, states that nausea, vomiting, diarrhea and the other stomach reactions were most frequently reported during dosage escalation. It also explains why the escalation schedule exists at all: the label instructs prescribers to follow the step-up table to reduce the risk of gastrointestinal adverse reactions, and says that if a patient does not tolerate a dose during escalation, delaying the next step for four weeks can be considered. That is a decision for the prescriber, but the existence of the instruction tells you that a rough week after a step up was anticipated.

The tirzepatide labels say the same thing with a mechanism attached. Both the Zepbound and Mounjaro prescribing information state that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time, and in their clinical pharmacology sections both state that tirzepatide delays gastric emptying, that the delay is largest after the first dose, and that this effect diminishes over time. In plain terms, each new dose level is a small version of the first dose: the stomach slows more than it will once your body has adjusted, and food that sits longer is more likely to come back up as nausea. Semaglutide's label states that it delays gastric emptying too, though it does not describe the first-dose peak in the same words.

What separates expected from not: the Wegovy Medication Guide tells patients to contact their healthcare provider if nausea, vomiting or diarrhea does not go away, because fluid loss can lead to kidney problems, and to stop the drug and call right away for severe abdominal pain that will not go away, with or without vomiting, which can be a sign of pancreatitis. Nausea that fades over several days after the increase is on the label; nausea that stops you keeping fluids down is on the warning list. The practical side, including the meal patterns people report help most, is in our guide to GLP-1 nausea.

Both are normal, for different reasons. On the first: every once-weekly GLP-1 medication for weight reduction starts at a low dosage and steps up over months, and the labels are explicit that the starting level is not the treatment. The Zepbound label states that its starting dosage is for treatment initiation and is not approved as a maintenance dose. The Wegovy label's escalation table runs across weeks one through sixteen before the maintenance dosage begins, and in the SELECT cardiovascular trial described in the same label, the dose-escalation period was sixteen weeks. Zepbound's Studies 1 and 2 used an escalation period of up to twenty weeks. The pivotal-trial weight-loss figures everyone quotes were measured at week 68 for Wegovy and week 72 for Zepbound, after at least a year at maintenance. Judging the medication by week three is judging it before it has been given.

It is also worth knowing that some people do not respond even after the full course. In Wegovy Study 2, 83.5% of injection-treated adults lost at least 5% of their body weight by week 68 versus 31.1% on placebo, which means roughly one in six did not reach that threshold. In Zepbound Study 1, 85% to 91% across the three maintenance doses reached the 5% mark versus 35% on placebo. Those are strong odds, not certainties, and a genuine stall after months at maintenance is a conversation for the prescriber. Our guide to a GLP-1 weight-loss plateau covers how to tell an early-weeks pause from a real plateau.

On the overnight jump: a bathroom scale weighs everything in the body at that moment, including water, the glycogen that holds water with it, salt, and food that has not yet left a stomach that the label says is emptying more slowly. None of that is fat, and all of it moves day to day. The clearest evidence that this is ordinary comes from a study by Orsama and colleagues published in Obesity Facts in 2014, which analyzed 4,657 daily weigh-ins from 80 adults and found a repeating weekly rhythm: weight was highest on Sunday and Monday and fell through the working week, and the pattern was strongest in people who were losing or maintaining weight overall. A higher number on Monday morning is a pattern, not a verdict. The measurement that matters is the weekly trend, which is why logging weight on the same weekday, at the same time, in the same state, gives you a line you can trust rather than a series of frights.

Tiredness is on both weight-management labels. The Wegovy prescribing information reports fatigue in 11% of adults on the injection versus 5% on placebo, and the footnote says the category includes asthenia, the clinical term for lack of strength. The Zepbound label reports fatigue in 5%, 6% and 7% across its three maintenance doses versus 3% on placebo, with a broader footnote that groups asthenia, fatigue, lethargy and malaise together. Mounjaro's diabetes table does not reach the 5% threshold for fatigue, but the same label reports it in 10% of the 6,647 adults in the SURPASS-CVOT cardiovascular outcomes trial. So yes, feeling tired is commonly reported; the more useful question is what is driving it, because a reduced-calorie diet, drinking less, sleeping worse and, for people on insulin or a sulfonylurea, low blood sugar all produce the same feeling. Our guide to GLP-1 fatigue separates those causes and lists the label red flags that share the symptom.

Feeling full after a few bites is closer to the mechanism than to a side effect. The Zepbound label states that tirzepatide decreases calorie intake, likely by affecting appetite, and the Mounjaro table records decreased appetite in 5% to 11% of adults with type 2 diabetes versus 1% on placebo. The Wegovy label describes GLP-1 as a physiological regulator of appetite and caloric intake and states that semaglutide delays gastric emptying. Early fullness is those two effects arriving at the same meal. It becomes a problem when it crowds out protein and fluid: the Wegovy Medication Guide's instruction to drink fluids is there because nausea, vomiting and diarrhea can cause dehydration and kidney problems, and a small appetite makes it easy to drink less as well. Our guide to protein on a GLP-1 covers how people make room for it on a small appetite.

Feeling cold is different: it is not in the Wegovy, Zepbound or Mounjaro adverse-reaction tables, and none of the three labels lists it anywhere as a reported reaction. That does not make it imaginary; it makes it unmeasured. People eating substantially less and losing body fat commonly describe it, and it usually travels with the same reduced intake that drives the fatigue. Because there is no trial frequency to quote, the honest answer is that feeling cold is widely reported and undocumented, and that persistent cold with other symptoms, such as marked tiredness, hair loss or changes in heart rate, is worth raising at the next appointment rather than searching for online.

Burping is on the label; the smell is not. The medical term is eructation, and the Wegovy prescribing information reports it in 7% of adults on the injection versus under 1% on placebo, while the Zepbound label reports 4% to 5% across its three maintenance doses versus 1%. No label records odor. The rotten-egg character people describe is hydrogen sulfide, which a 2012 Frontiers in Physiology review by Carbonero and colleagues attributes to gut bacteria acting on sulfur compounds, and per both labels the food those bacteria work on is leaving the stomach more slowly. It is unpleasant and commonly reported; it is not a warning sign on its own. Where it does become one is when the belching arrives with severe or persistent abdominal pain, repeated vomiting or an inability to pass gas or stool, because the Wegovy label lists ileus and intestinal obstruction among postmarketing reports. Our guide to GLP-1 sulfur burps goes through the label figures and the food patterns people log alongside them.

Constipation is one of the larger numbers in the tables: 24% on the Wegovy injection versus 11% on placebo, 11% to 17% on Zepbound versus 5%, and 6% to 7% on Mounjaro versus 1% in adults with type 2 diabetes. The Zepbound footnote adds that its category includes hard stools. Slower gastric emptying, less food volume and less fluid all point the same way. The Wegovy label's postmarketing section also lists severe constipation, so the distinction is between fewer, harder bowel movements, which is expected, and constipation with severe pain, swelling or vomiting, which is not. Our guide to GLP-1 constipation has the detail.

Hair loss is on both weight-management labels and both manufacturers attach the same explanation. The Wegovy label reports hair loss in 3% of adults on the injection versus 1% on placebo, and in its detailed note says hair loss adverse reactions were associated with weight reduction, with 3.3% of patients in a pool of Studies 2, 3 and 4 reporting it (4% of women, 0.9% of men) versus 1% on placebo. The Zepbound label reports 4% to 5% versus 1% and, in the same words, associates it with weight reduction, adding that it was reported in 7.1% of women versus 0.5% of men on tirzepatide, and that no tirzepatide-treated patient stopped treatment because of it. Hair coming out months into rapid weight loss is, on this evidence, commonly reported and tied to the loss rather than to the molecule. Our guide to GLP-1 hair loss covers timing, the shedding pattern dermatologists describe and what to log.

The clearest version of that line is printed in the Wegovy Medication Guide, and the Zepbound and Mounjaro guides carry near-identical lists. Stop the medication and call right away for severe pain in the stomach area that will not go away, with or without nausea or vomiting, sometimes felt through to the back, because that can be pancreatitis. Call for pain in the upper stomach with fever, yellowing of the skin or eyes, or clay-colored stools, because those are gallbladder signs. Tell your provider right away about nausea, vomiting or diarrhea that does not go away, because dehydration can lead to kidney problems. For people with type 2 diabetes, especially those also on insulin or a sulfonylurea, dizziness, sweating, shakiness, confusion, drowsiness or a fast heartbeat can be low blood sugar. Stop and get medical help right away for swelling of the face, lips, tongue or throat, severe rash, trouble breathing or swallowing, or fainting. And tell your provider if your heart races or pounds at rest for several minutes, because the labels note an increase in resting heart rate.

Everything else on this page, nausea that fades after a step up, a slow first month, tiredness, early fullness, sulfur burps, harder stools, a shedding phase and a Monday-morning scale jump, sits on the commonly-reported side. The word normal is doing two jobs there. It means the manufacturers counted it in the trials, and it means it does not, by itself, need a call. It does not mean you should put up with it silently: the same prescribing information that lists these reactions also describes delaying escalation and adjusting other medications as tools the prescriber has, and a pharmacist can walk through the interaction and hydration points in the Medication Guide. Bring the specifics rather than the word bad.

Specifics are what a log is for. For each symptom, record the date, what it was, how severe it felt on a simple scale, how many days since your last injection, whether that injection was the first at a new level, and roughly what and how much you ate and drank. Weigh on the same weekday at the same time. Over a few weeks the entries answer the is-it-normal question in your own data: nausea that clusters in the three days after an increase and thins out by the next one is the label's pattern; nausea that is flat across the week and getting worse is not. GLP-1 Tracker (free, iPhone, no account, data stored on your device) keeps injections, meals, weight and symptom notes on one timeline for exactly this comparison, and our how-to on keeping a GLP-1 symptom journal shows the format. When the appointment comes, our list of questions to ask at a GLP-1 follow-up turns the log into a conversation.